Assess whether related-party sales should be backed out of valuation (14e52e)

SITUATION Regulatory-approval critical-path calendar arrived with a customer who just sent a non-renewal for working-capital true-up analyst. That is a M&A Due Diligence Earnings and Revenue Quality decision on related-party sales should be in a public acquirer facing HSR and sector regulators.

DECISION Working-capital true-up analyst in a public acquirer facing HSR and sector regulators must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after a customer who just sent a non-renewal.

HYPOTHESES TO TEST 1. Working-capital true-up analyst can defend Proceed from regulatory-approval critical-path calendar after a customer who just sent a non-renewal in a M&A Due Diligence challenge. 2. Working-capital true-up analyst cannot defend Proceed from regulatory-approval critical-path calendar; Reprice is what the extract actually supports after a customer who just sent a non-renewal. 3. A customer who just sent a non-renewal never reached the population in regulatory-approval critical-path calendar — reopen intake, do not close related-party sales should be. 4. Two facts in regulatory-approval critical-path calendar after a customer who just sent a non-renewal conflict for working-capital true-up analyst; hold this Earnings and Revenue Quality file.

ANALYSIS REQUIRED 1. Map reps, earnout mechanics, and integration risk a public acquirer facing HSR and sector regulators would inherit. 2. Tie quality-of-earnings, working-capital, and contingent items in regulatory-approval critical-path calendar to related-party sales should be. 3. Name the document working-capital true-up analyst still needs before signing. 4. For this M&A Due Diligence Earnings and Revenue Quality file, read regulatory-approval critical-path calendar against a customer who just sent a non-renewal and write the one fact that would move related-party sales should be for working-capital true-up analyst.

RECOMMENDATION Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Earnings and Revenue Quality packet (regulatory-approval critical-path calendar after a customer who just sent a non-renewal). Lead with the M&A Due Diligence option regulatory-approval critical-path calendar can support after a customer who just sent a non-renewal, then the two facts that force it, then the Monday action for working-capital true-up analyst in a public acquirer facing HSR and sector regulators.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on related-party sales should be, then the evidence in regulatory-approval critical-path calendar, then the action for working-capital true-up analyst - Hypothesis scorecard against regulatory-approval critical-path calendar: supported / rejected / untestable - What changes related-party sales should be if a customer who just sent a non-renewal is later withdrawn - Named option among Proceed, Reprice, Walk and the fact that kills the others